EGFR and neoplasm: It has been reported that the activation of the PD-1/PD-L1 pathway contributes to immunosuppression during anti-tumor therapy in EGFR-driven lung tumors by suppressing T-cell function and increasing the release of pro-inflammatory cytokines (Akbay et al., 2013).